title: Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
abstract: BACKGROUND
  Venous thrombo-embolic events (VTEs) occur in 2.2% to 14% of paediatric cancer patients and cause significant morbidity and mortality. The malignant disease itself, the cancer treatment and the presence of central venous catheters (CVCs) increase the risk of VTE.
  
  
  OBJECTIVE
  The primary objective of this review was to investigate the effects of preventive systemic treatments in paediatric cancer patients with tunnelled CVCs on (a)symptomatic VTE. Secondary objectives of this review were to investigate adverse effects of systemic treatments for the prevention of (a)symptomatic VTE in paediatric cancer patients with tunnelled CVCs; and to investigate the effects of systemic treatments in the prevention of (a)symptomatic VTE with CVC-related infection in paediatric cancer patients with tunnelled CVCs.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 8 2012), MEDLINE (1966 to August 2012) and EMBASE (1966 to August 2012). In addition, we searched reference lists from relevant articles and conference proceedings of the International Society for Paediatric Oncology (SIOP) (from 2006 to 2011), the American Society of Clinical Oncology (ASCO) (from 2006 to 2011), the American Society of Hematology (ASH) (from 2006 to 2011) and the International Society of Thrombosis and Haematology (ISTH) (from 2006 to 2011). We scanned the International Standard Randomised Controlled Trial Number (ISRCTN) Register and the National Institute of Health (NIH) Register for ongoing trials (www.controlled-trials.com) (August 2012), and we contacted the authors of eligible studies if additional information was required.
  
  
  METHODS
  Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing systemic treatments to prevent venous thrombo-embolic events (VTEs) in paediatric cancer patients with tunnelled CVCs with a control intervention or no systemic treatment. For the description of adverse events, cohort studies were eligible for inclusion.
  
  
  METHODS
  Two review authors independently selected studies, extracted data and performed risk of bias assessment of included studies. Analyses were performed according to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions.
  
  
  RESULTS
  Three RCTs and three CCTs (including 1291 children) investigated the prevention of VTE (low molecular weight heparin (LMWH) n = 134, antithrombin (AT) supplementation n = 37, low-dose warfarin n = 31, cryoprecipitate and/or fresh frozen plasma (FFP) supplementation n = 240, AT supplementation and LMWH n = 41). AT, cryoprecipitate and FFP were supplemented only in cases of AT or fibrinogen deficiency. Of the six included RCTs/CCTs, five investigated the prevention of VTE compared with no intervention (n = 737), and one CCT compared AT supplementation and LMWH with AT supplementation (n = 71). All studies had methodological limitations, and clinical heterogeneity between studies was noted.We found no significant effects of systemic treatments compared with no intervention in preventing (a)symptomatic VTE and no differences in adverse events (such as major and/or minor bleeding; none of the studies reported thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia with thrombosis (HITT), death as a result of VTE, removal of CVC due to VTE, CVC-related infection, and post-thrombotic syndrome (PTS)) between experimental and control groups. Two studies with comparable participant groups and interventions were included for meta-analyses (n = 182). In the experimental group, 1/68 (1.5%) children were diagnosed with symptomatic VTE, as were 4/114 (3.5%) in the control group (best case scenario: risk ratio (RR) 0.65, 95% confidence interval (CI) 0.09 to 4.78). These studies also evaluated asymptomatic CVC-related VTE: In the experimental group, 22/68 (32.4%) were diagnosed with asymptomatic VTE, as were 35/114 (30.7%) in the control group (best case scenario: RR 1.02, 95% CI 0.40 to 2.55). Heterogeneity was substantial for this analysis: I(2) = 73%.The attribution of LMWH to AT supplementation resulted in a significant reduction in symptomatic VTE (Fisher's exact test, two-sided P = 0.028) without bleeding complications; asymptomatic VTE, thrombocytopenia, HIT, HITT, death as a result of VTE, removal of CVC due to VTE, CVC-related infection and PTS were not assessed.Four cohort studies were included for the evaluation of adverse events. Three studies provided information on bleeding episodes: One participant developed an ischaemo-haemorrhagic stroke. One study provided information on other adverse events: None occurred.
  
  
  CONCLUSIONS
  We found no significant effects of systemic treatments compared with no intervention in preventing (a)symptomatic VTE in paediatric oncology patients with CVCs. However, this could be a result of the low number of included participants, which resulted in low power. In one CCT, which compared one systemic treatment with another systemic treatment, we identified a significant reduction in symptomatic VTE with the addition of LMWH to AT supplementation.All studies investigated the prevalence of major and/or minor bleeding episodes, and none found a significant difference between study groups. None of the studies reported thrombocytopenia, HIT, HITT, death as a result of VTE, removal of CVC due to VTE, CVC-related infection or PTS among participants.On the basis of currently available evidence, we are not able to give recommendations for clinical practise. Additional well-designed international RCTs are needed to further explore the effects of systemic treatments in preventing VTE. Future studies should aim for adequate power with attainable sample sizes. The incidence of symptomatic VTE is relatively low; therefore, it might be necessary to select participants with thrombotic risk factors or to investigate asymptomatic VTE instead.
authors.affiliation: Department of Paediatric Oncology, Emma Children's Hospital / Academic Medical Center, PO Box 22660, Amsterdam, Netherlands, 1100 DD.
authors.forename: Reineke A
authors.initials: RA
authors.lastname: Schoot
authors.forename: Leontien C M
authors.initials: LC
authors.lastname: Kremer
authors.forename: Marianne D
authors.initials: MD
authors.lastname: van de Wetering
authors.forename: Cornelia H
authors.initials: CH
authors.lastname: van Ommen
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000627:therapeutic use; D062905:Central Venous Catheters / Q000009:adverse effects*; D002648:Child; D018849:Controlled Clinical Trials as Topic; D005169:Factor VIII / Q000627:therapeutic use; D005340:Fibrinogen / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D010949:Plasma; D016032:Randomized Controlled Trials as Topic; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D006495:Heparin, Low-Molecular-Weight; C026912:cryoprecipitate coagulum; D014859:Warfarin; D005169:Factor VIII; D005340:Fibrinogen
references.citation: J Pediatr. 2001 Nov;139(5):676-81
references.pmid: 11713446
references.citation: J Pediatr Hematol Oncol. 2003 Nov;25(11):864-7
references.pmid: 14608195
references.citation: Support Care Cancer. 2002 Apr;10(3):253-5
references.pmid: 11904791
references.citation: Pediatr Hematol Oncol. 2002 Apr-May;19(3):173-9
references.pmid: 11936730
references.citation: Clin Infect Dis. 2009 Dec 1;49(11):1770-1; author reply 1771-2
references.pmid: 19891568
references.citation: J Pediatr. 1998 Dec;133(6):770-6
references.pmid: 9842042
references.citation: Cancer. 2010 Sep 1;116(17):4197-205
references.pmid: 20533566
references.citation: Support Care Cancer. 2002 Apr;10(3):258-9; author reply 260-1
references.pmid: 11904793
references.citation: Thromb Haemost. 2004 Sep;92(3):654-61
references.pmid: 15351864
references.citation: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006468
references.pmid: 17636845
references.citation: Curr Opin Oncol. 2003 Jul;15(4):289-92
references.pmid: 12874506
references.citation: Semin Thromb Hemost. 1999;25(2):137-45
references.pmid: 10357081
references.citation: Ann Oncol. 2005 Apr;16(4):648-54
references.pmid: 15677621
references.citation: Pediatr Blood Cancer. 2008 Apr;50(4):826-30
references.pmid: 17729250
references.citation: Acta Paediatr. 2006 Sep;95(9):1049-52
references.pmid: 16938748
references.citation: Clin Infect Dis. 2003 Jan 1;36(1):116-9
references.pmid: 12491212
references.citation: Blood. 2009 Dec 10;114(25):5146-51
references.pmid: 19822902
references.citation: Pediatrics. 1989 Jun;83(6):963-6
references.pmid: 2657625
references.citation: Thromb Res. 2003;111(4-5):199-212
references.pmid: 14693164
references.citation: J Thromb Haemost. 2008 Apr;6(4):589-94
references.pmid: 18194413
references.citation: Pediatr Hematol Oncol. 1995 May-Jun;12(3):243-50
references.pmid: 7640177
references.citation: J Pediatr Surg. 1996 Jun;31(6):816-8
references.pmid: 8783111
references.citation: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008500
references.pmid: 22336844
references.citation: Support Care Cancer. 2001 Oct;9(7):539-44
references.pmid: 11680834
references.citation: Haematologica. 2010 Nov;95(11):1952-9
references.pmid: 20595095
references.citation: Pediatr Blood Cancer. 2008 Feb;50(2):298-303
references.pmid: 17443678
references.citation: Leukemia. 2007 Mar;21(3):552-6
references.pmid: 17268522
references.citation: Am J Pediatr Hematol Oncol. 1991 Summer;13(2):141-3
references.pmid: 2069221
references.citation: Thromb Res. 2003 Jan 25;109(2-3):93-9
references.pmid: 12706637
references.citation: Am J Infect Control. 2008 Feb;36(1):54-8
references.pmid: 18241737
references.citation: J Pediatr Surg. 2010 Oct;45(10):1961-6
references.pmid: 20920713
references.citation: Acta Paediatr. 2006 Sep;95(9):1053-9
references.pmid: 16938749
references.citation: Pediatr Hematol Oncol. 2006 Apr-May;23(3):207-16
references.pmid: 16517537
references.citation: Pediatrics. 1998 Feb;101(2):E7
references.pmid: 9445517
references.citation: Recent Pat Cardiovasc Drug Discov. 2007 Jan;2(1):53-62
references.pmid: 18221103
references.citation: Pediatr Hematol Oncol. 1986;3(1):19-25
references.pmid: 3153215
references.citation: Haemophilia. 2008 Jan;14(1):30-8
references.pmid: 18005145
references.citation: N Engl J Med. 2006 Jun 1;354(22):2317-27
references.pmid: 16738268
references.citation: JAMA. 1990 May 23-30;263(20):2753-9
references.pmid: 2332918
references.citation: Thromb Res. 2008;122(6):826-30
references.pmid: 18207492
references.citation: JAMA. 2005 Feb 9;293(6):715-22
references.pmid: 15701913
references.citation: Blood Coagul Fibrinolysis. 2001 Jul;12(5):367-70
references.pmid: 11505079
references.citation: J Thromb Haemost. 2007 Dec;5(12):2552-4
references.pmid: 18034768
references.citation: Circulation. 2008 Sep 23;118(13):1373-82
references.pmid: 18779442
references.citation: J Clin Oncol. 2009 Apr 20;27(12):2059-65
references.pmid: 19273702
references.citation: Clin Oncol (R Coll Radiol). 2006 Mar;18(2):145-51
references.pmid: 16523816
references.citation: Eur J Cancer. 2004 Oct;40(15):2253-9
references.pmid: 15454250
references.citation: BMC Cancer. 2012 Jul 26;12:314
references.pmid: 22835078
references.citation: J Hosp Infect. 2012 Apr;80(4):304-9
references.pmid: 22342714
references.citation: Cochrane Database Syst Rev. 2013 Sep 11;(9):CD009160
references.pmid: 24026801
references.citation: J Vasc Access. 2008 Jan-Mar;9(1):51-7
references.pmid: 18379981
references.citation: Eur J Pediatr. 1999 Dec;158 Suppl 3:S147-50
references.pmid: 10650856
references.citation: Thromb Res. 2010 Aug;126(2):93-7
references.pmid: 20546854
references.citation: Thromb Res. 2003 Jan 25;109(2-3):101-8
references.pmid: 12706638
references.citation: Curr Opin Hematol. 2003 Sep;10(5):369-74
references.pmid: 12913792
references.citation: Acta Paediatr. 2006 Sep;95(9):1060-5
references.pmid: 16938750
references.citation: J Thromb Thrombolysis. 2008 Oct;26(2):138-41
references.pmid: 17701104
references.citation: J Thromb Haemost. 2010 Jul;8(7):1649-51
references.pmid: 20456756
references.citation: Blood. 1994 Mar 1;83(5):1251-7
references.pmid: 8118029
references.citation: Blood. 2010 Jun 17;115(24):4999-5004
references.pmid: 20339086
references.citation: J Clin Oncol. 2000 Mar;18(6):1269-78
references.pmid: 10715297
references.citation: Eur J Cancer Care (Engl). 2009 Mar;18(2):191-4
references.pmid: 19267736
references.citation: Thorax. 1993 May;48(5):558-9
references.pmid: 8322245
references.citation: J Pediatr Hematol Oncol. 2012 Apr;34(3):188-93
references.pmid: 22278202
references.citation: Support Care Cancer. 2004 Dec;12(12):840-3
references.pmid: 15365798
references.citation: Leuk Lymphoma. 2003 Sep;44(9):1495-501
references.pmid: 14565650
references.citation: Thromb Haemost. 1999 Sep;82(3):1008-10
references.pmid: 10494754
references.citation: Semin Thromb Hemost. 2007 Jun;33(4):416-26
references.pmid: 17525899
references.citation: Int Angiol. 2004 Sep;23(3):195-205
references.pmid: 15765033
references.citation: Tunis Med. 2000 Nov;78(11):641-7
references.pmid: 11155387
references.citation: Thromb Haemost. 2003 Aug;90(2):235-44
references.pmid: 12888870
references.citation: J Vasc Interv Radiol. 2010 Dec;21(12):1852-8
references.pmid: 21111365
references.citation: J Pediatr. 1995 Mar;126(3):358-63
references.pmid: 7869192
references.citation: Arch Intern Med. 2000 Mar 27;160(6):761-8
references.pmid: 10737275
references.citation: J Clin Oncol. 2004 Jul 1;22(13):2718-23
references.pmid: 15226339
references.citation: Chemotherapy. 2011;57(4):285-91
references.pmid: 21778716
references.citation: J Clin Oncol. 2006 Oct 1;24(28):4575-80
references.pmid: 17008698
references.citation: J Pediatr Oncol Nurs. 2010 Nov-Dec;27(6):325-9
references.pmid: 20657002
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4063-9
references.pmid: 15767639